ID21863A - Senyawa kinolin dan kinazolin yangberguna dalam terapi, khususnya dalam pengobatan heperplasia prostatik jinak - Google Patents

Senyawa kinolin dan kinazolin yangberguna dalam terapi, khususnya dalam pengobatan heperplasia prostatik jinak

Info

Publication number: ID21863A
Authority: ID; Indonesia
Prior art keywords: heperplasia; kinazolin; kinolin; prostatic; therapy
Prior art date: 1997-01-11

Application number

IDW990660A

Other languages

English (en)

Inventor

Fox David Nathan Abraham

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-11

Filing date

1998-01-06

Publication date

1999-08-05

1998-01-06 Application filed by Pfizer filed Critical Pfizer

1999-08-05 Publication of ID21863A publication Critical patent/ID21863A/id

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IDW990660A 1997-01-11 1998-01-06 Senyawa kinolin dan kinazolin yangberguna dalam terapi, khususnya dalam pengobatan heperplasia prostatik jinak ID21863A (id)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9700504.5A GB9700504D0 (en)	1997-01-11	1997-01-11	Pharmaceutical compounds

Publications (1)

Publication Number	Publication Date
ID21863A true ID21863A (id)	1999-08-05

Family

ID=10805838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW990660A ID21863A (id)	1997-01-11	1998-01-06	Senyawa kinolin dan kinazolin yangberguna dalam terapi, khususnya dalam pengobatan heperplasia prostatik jinak

Country Status (45)

Country	Link
US (4)	US6169093B1 (id)
EP (1)	EP0968208B1 (id)
JP (1)	JP3357677B2 (id)
KR (1)	KR100347472B1 (id)
CN (2)	CN1093858C (id)
AP (1)	AP819A (id)
AR (1)	AR010396A1 (id)
AT (1)	ATE242238T1 (id)
AU (1)	AU724990B2 (id)
BG (1)	BG63918B1 (id)
BR (1)	BR9807068A (id)
CA (1)	CA2277473C (id)
CZ (1)	CZ295580B6 (id)
DE (1)	DE69815313T2 (id)
DK (1)	DK0968208T3 (id)
DZ (1)	DZ2394A1 (id)
EA (1)	EA002851B1 (id)
ES (1)	ES2198695T3 (id)
GB (1)	GB9700504D0 (id)
HK (1)	HK1054389B (id)
HN (1)	HN1998000002A (id)
HR (1)	HRP980010B1 (id)
HU (1)	HUP0000942A3 (id)
ID (1)	ID21863A (id)
IL (1)	IL130762A (id)
IS (1)	IS2012B (id)
MA (1)	MA26465A1 (id)
MY (1)	MY119623A (id)
NO (1)	NO318609B1 (id)
NZ (1)	NZ336302A (id)
OA (1)	OA11074A (id)
PA (1)	PA8444301A1 (id)
PE (1)	PE44499A1 (id)
PL (1)	PL334678A1 (id)
PT (1)	PT968208E (id)
SA (1)	SA97180705B1 (id)
SI (1)	SI0968208T1 (id)
SK (1)	SK284779B6 (id)
TN (1)	TNSN98004A1 (id)
TR (1)	TR199901604T2 (id)
TW (1)	TW444013B (id)
UA (1)	UA62945C2 (id)
WO (1)	WO1998030560A1 (id)
YU (1)	YU31699A (id)
ZA (1)	ZA98166B (id)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9700504D0 (en)	1997-01-11	1997-02-26	Pfizer Ltd	Pharmaceutical compounds
GB9708917D0 (en) *	1997-05-01	1997-06-25	Pfizer Ltd	Compounds useful in therapy
IL141235A (en)	2000-02-09	2012-04-30	Novartis Int Pharm Ltd	Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
AU779118B2 (en) *	2000-03-03	2005-01-06	Pfizer Inc.	4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3, 4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs
KR100602929B1 (ko)	2000-08-31	2006-07-20	에프. 호프만-라 로슈 아게	알파-1 아드레날린성 길항제로서 퀴나졸린 유도체
US6900220B2 (en)	2001-01-02	2005-05-31	Syntex (U.S.A.) Llc	Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
CA2432578C (en) *	2001-01-02	2008-04-01	F. Hoffmann-La Roche Ag	Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US6734303B2 (en)	2001-05-18	2004-05-11	Pfizer Inc.	Process for the production of quinazolines
GB0112061D0 (en) *	2001-05-18	2001-07-11	Pfizer Ltd	Process for the production of quinazolines
GB0118752D0 (en) *	2001-08-01	2001-09-26	Pfizer Ltd	Process for the production of quinazolines
GB0124455D0 (en) *	2001-10-11	2001-12-05	Pfizer Ltd	Pharmaceutical formulations
US7163696B2 (en)	2001-10-11	2007-01-16	Pfizer Inc.	Pharmaceutical formulations
GB0206033D0 (en)	2002-03-14	2002-04-24	Pfizer Ltd	Compounds useful in therapy
EP1521747B1 (en)	2002-07-15	2018-09-05	Symphony Evolution, Inc.	Receptor-type kinase modulators and methods of use
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
GB0221582D0 (en) *	2002-09-17	2002-10-23	Pfizer Ltd	Method of treatment
GB0221579D0 (en) *	2002-09-17	2002-10-23	Pfizer Ltd	Combinations of atorvastatin and, adrenergic receptor antagonists
MXPA05002004A (es)	2002-09-26	2005-04-28	Pfizer	Derivados de pirazol.
GB0225908D0 (en) *	2002-11-06	2002-12-11	Pfizer Ltd	Treatment of female sexual dysfunction
PT1572173E (pt)	2002-12-13	2010-05-10	Warner Lambert Co	Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
EP1644343B1 (en) *	2003-07-02	2007-07-04	F. Hoffmann-La Roche Ag	5-substituted quinazolinone derivatives
US7291640B2 (en)	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
EP2210607B1 (en) *	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
KR20050092519A (ko) *	2004-03-16	2005-09-22	화이자 인코포레이티드	아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
WO2005089804A2 (en) *	2004-03-16	2005-09-29	Pfizer Limited	Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
AP2006003771A0 (en)	2004-04-30	2006-10-31	Warner Lambert Co	Substituted morpholine compounds for the treatmentof central nervous system disorders
WO2008084493A2 (en) *	2007-01-09	2008-07-17	Unichem Laboratories Limited	A novel process for the preparation of 2-halo-4-aminoquinazolines
JP2009126784A (ja) *	2007-11-19	2009-06-11	Mitsubishi Gas Chem Co Inc	２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法。
JP2009126785A (ja) *	2007-11-19	2009-06-11	Mitsubishi Gas Chem Co Inc	２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法
TW201920110A (zh)	2009-01-16	2019-06-01	美商艾克塞里克斯公司	包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP6377245B2 (ja) *	2014-03-24	2018-08-22	グアンドンジョンシェンファーマシューティカルカンパニーリミテッド	Ｓｍｏ阻害剤としてのキノリン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US875506A (en) *	1907-03-19	1907-12-31	Berry H Collins	Guiding attachment for penholders.
GB1390014A (en) *	1971-05-07	1975-04-09	Koninklijke Pharma Fab Nv	Process for the preparation of carbocyclic fused pyrimidine derivatives
US4026894A (en) *	1975-10-14	1977-05-31	Abbott Laboratories	Antihypertensive agents
US4098788A (en) *	1977-06-20	1978-07-04	Bristol-Myers Company	Process for preparing quinazolines
GR79603B (id) *	1982-07-24	1984-10-31	Pfizer
GB8506174D0 (en) *	1985-03-09	1985-04-11	Pfizer Ltd	4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IT1270993B (it) *	1994-03-18	1997-05-26	Recordati Chem Pharm	Derivati chinzolilamminici attivi come alfa-antagonisti
GB9526546D0 (en)	1995-12-23	1996-02-28	Pfizer Ltd	Compounds useful in therapy
GB9700504D0 (en)	1997-01-11	1997-02-26	Pfizer Ltd	Pharmaceutical compounds
GB9708917D0 (en) *	1997-05-01	1997-06-25	Pfizer Ltd	Compounds useful in therapy
GB9711650D0 (en)	1997-06-05	1997-07-30	Pfizer Ltd	Compounds useful in therapy

1997
- 1997-01-11 GB GBGB9700504.5A patent/GB9700504D0/en active Pending
- 1997-11-18 TW TW086117203A patent/TW444013B/zh not_active IP Right Cessation
- 1997-12-13 SA SA97180705A patent/SA97180705B1/ar unknown
1998
- 1998-01-05 PE PE1998000006A patent/PE44499A1/es not_active Application Discontinuation
- 1998-01-05 HN HN1998000002A patent/HN1998000002A/es unknown
- 1998-01-06 EA EA199900531A patent/EA002851B1/ru not_active IP Right Cessation
- 1998-01-06 KR KR1019997006241A patent/KR100347472B1/ko not_active Expired - Fee Related
- 1998-01-06 TR TR1999/01604T patent/TR199901604T2/xx unknown
- 1998-01-06 PL PL98334678A patent/PL334678A1/xx unknown
- 1998-01-06 HU HU0000942A patent/HUP0000942A3/hu unknown
- 1998-01-06 CN CN98801748A patent/CN1093858C/zh not_active Expired - Fee Related
- 1998-01-06 SI SI9830477T patent/SI0968208T1/xx unknown
- 1998-01-06 WO PCT/EP1998/000143 patent/WO1998030560A1/en not_active Ceased
- 1998-01-06 NZ NZ336302A patent/NZ336302A/xx unknown
- 1998-01-06 SK SK907-99A patent/SK284779B6/sk unknown
- 1998-01-06 AP APAP/P/1998/001175A patent/AP819A/en active
- 1998-01-06 DK DK98904058T patent/DK0968208T3/da active
- 1998-01-06 ES ES98904058T patent/ES2198695T3/es not_active Expired - Lifetime
- 1998-01-06 DE DE69815313T patent/DE69815313T2/de not_active Expired - Lifetime
- 1998-01-06 US US09/341,228 patent/US6169093B1/en not_active Expired - Lifetime
- 1998-01-06 ID IDW990660A patent/ID21863A/id unknown
- 1998-01-06 YU YU31699A patent/YU31699A/sh unknown
- 1998-01-06 CN CNB011432918A patent/CN1191249C/zh not_active Expired - Fee Related
- 1998-01-06 PA PA19988444301A patent/PA8444301A1/es unknown
- 1998-01-06 CZ CZ19992436A patent/CZ295580B6/cs not_active IP Right Cessation
- 1998-01-06 BR BR9807068-1A patent/BR9807068A/pt not_active Application Discontinuation
- 1998-01-06 JP JP53056598A patent/JP3357677B2/ja not_active Expired - Lifetime
- 1998-01-06 PT PT98904058T patent/PT968208E/pt unknown
- 1998-01-06 EP EP98904058A patent/EP0968208B1/en not_active Expired - Lifetime
- 1998-01-06 AT AT98904058T patent/ATE242238T1/de not_active IP Right Cessation
- 1998-01-06 CA CA002277473A patent/CA2277473C/en not_active Expired - Fee Related
- 1998-01-06 IL IL13076298A patent/IL130762A/xx not_active IP Right Cessation
- 1998-01-06 AU AU62088/98A patent/AU724990B2/en not_active Ceased
- 1998-01-07 TN TNTNSN98004A patent/TNSN98004A1/fr unknown
- 1998-01-07 MA MA24920A patent/MA26465A1/fr unknown
- 1998-01-08 HR HR980010A patent/HRP980010B1/xx not_active IP Right Cessation
- 1998-01-08 AR ARP980100091A patent/AR010396A1/es unknown
- 1998-01-09 MY MYPI98000094A patent/MY119623A/en unknown
- 1998-01-09 ZA ZA98166A patent/ZA98166B/xx unknown
- 1998-06-01 UA UA99073901A patent/UA62945C2/uk unknown
- 1998-06-07 DZ DZ980004A patent/DZ2394A1/xx active
1999
- 1999-06-25 IS IS5093A patent/IS2012B/is unknown
- 1999-07-07 BG BG103560A patent/BG63918B1/bg unknown
- 1999-07-08 OA OA9900152A patent/OA11074A/en unknown
- 1999-07-09 NO NO19993396A patent/NO318609B1/no unknown
2000
- 2000-06-02 US US09/586,503 patent/US6365599B1/en not_active Expired - Fee Related
2001
- 2001-11-13 US US10/007,753 patent/US6521629B2/en not_active Expired - Fee Related
2002
- 2002-12-13 US US10/318,902 patent/US6653302B2/en not_active Expired - Fee Related
2003
- 2003-09-17 HK HK03106677.4A patent/HK1054389B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1243513A (zh)	2000-02-02
GB9700504D0 (en)	1997-02-26
NO993396D0 (no)	1999-07-09
DE69815313T2 (de)	2003-12-11
NO993396L (no)	1999-07-09
PE44499A1 (es)	1999-05-06
SK90799A3 (en)	2001-03-12
IL130762A0 (en)	2001-01-28
US6365599B1 (en)	2002-04-02
PL334678A1 (en)	2000-03-13
ES2198695T3 (es)	2004-02-01
HUP0000942A2 (hu)	2001-04-28
AP9801175A0 (en)	1998-01-31
JP2000507966A (ja)	2000-06-27
MY119623A (en)	2005-06-30
HK1025327A1 (en)	2000-11-10
ATE242238T1 (de)	2003-06-15
CN1403453A (zh)	2003-03-19
CA2277473C (en)	2003-08-12
CZ9902436A3 (cs)	2000-10-11
PA8444301A1 (es)	2000-05-24
OA11074A (en)	2002-03-13
SI0968208T1 (en)	2003-10-31
HRP980010B1 (en)	2002-06-30
CN1093858C (zh)	2002-11-06
WO1998030560A1 (en)	1998-07-16
HN1998000002A (es)	1999-01-08
EP0968208B1 (en)	2003-06-04
CA2277473A1 (en)	1998-07-16
EA002851B1 (ru)	2002-10-31
BG103560A (en)	2000-06-30
NZ336302A (en)	2000-08-25
TNSN98004A1 (fr)	2005-03-15
PT968208E (pt)	2003-09-30
KR100347472B1 (ko)	2002-08-07
YU31699A (sh)	2001-07-10
SA97180705B1 (ar)	2005-12-26
IS5093A (is)	1999-06-25
DE69815313D1 (de)	2003-07-10
NO318609B1 (no)	2005-04-18
BR9807068A (pt)	2000-05-02
HUP0000942A3 (en)	2002-06-28
ZA98166B (en)	1999-07-09
AU724990B2 (en)	2000-10-05
BG63918B1 (bg)	2003-06-30
HK1054389B (zh)	2005-10-14
AP819A (en)	2000-04-03
AR010396A1 (es)	2000-06-07
DK0968208T3 (da)	2003-07-28
AU6208898A (en)	1998-08-03
US6653302B2 (en)	2003-11-25
TW444013B (en)	2001-07-01
CZ295580B6 (cs)	2005-08-17
TR199901604T2 (xx)	1999-12-21
US6169093B1 (en)	2001-01-02
HK1054389A1 (en)	2003-11-28
DZ2394A1 (fr)	2003-06-04
HRP980010A2 (en)	1998-10-31
KR20000070022A (ko)	2000-11-25
EP0968208A1 (en)	2000-01-05
JP3357677B2 (ja)	2002-12-16
MA26465A1 (fr)	2004-12-20
SK284779B6 (sk)	2005-11-03
EA199900531A1 (ru)	2000-02-28
CN1191249C (zh)	2005-03-02
US20020040028A1 (en)	2002-04-04
US20030130259A1 (en)	2003-07-10
IL130762A (en)	2005-12-18
IS2012B (is)	2005-05-13
US6521629B2 (en)	2003-02-18
UA62945C2 (en)	2004-01-15

Publication	Publication Date	Title
NO993396L (no)	1999-07-09	Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
ID25504A (id)	2000-10-05	Pencegahan dan pengobatan penyakit amiloidogenik
DE69836008D1 (de)	2006-11-09	Zusammensetzung und behandlungsmittel
ID26104A (id)	2000-11-23	Metoda-metoda dan bahan-bahan untuk mengobati dan mencegah radang jaringan mukosa
BR9608651A (pt)	1999-05-18	Método para o tratamento de hiperplasia prostática benigna com terapia térmica
ID27614A (id)	2001-04-12	Metode dan radas untuk terapi gelombang
ATE285767T1 (de)	2005-01-15	Kombinationstherapie, enthaltend atorvastatin und bluddrucksenkendes mittel
ID30116A (id)	2001-11-08	Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya
IS5510A (is)	2000-05-25	Efnasambönd sem verka gegn "picorna"-veirum og aðferðir til nota þeirra og smíða
EP0996433A4 (en)	2009-05-27	Methods for treatment of conditions associated with lactosylceramide
ID26861A (id)	2001-02-15	Terapi gabungan untuk pengobatan depresi refaktori
IS5504A (is)	2000-05-19	Samsetning virk við meðhöndlun á getuleysi
FI965204A0 (fi)	1996-12-23	Bromelaiinin lääkekäyttö
FI951060A7 (fi)	1995-09-09	Formulaatioita ja hoitomenetelmiä
DE69732024D1 (de)	2005-01-27	Haarbehandlungsmittel
ID17199A (id)	1997-12-11	Mikro-organisme pengurai hidrokarbon yang mengandung halogen dan pemakaiannya
ID24463A (id)	2000-07-20	Metode meningkatkan ketersediaan hayati feksofenadin dan turunan-turunannya
DE69828985D1 (de)	2005-03-17	Lichtgebender katheter sowie anwendungsverfahren
PT984777E (pt)	2004-01-30	Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
ID21847A (id)	1999-08-05	Komposisi insektisida dan metoda penggunaannya
ID28894A (id)	2001-07-12	Metoda dan komposisi untuk perlakuan terhadap penyakit gangguan gastro-esophageal
ZA981781B (en)	1999-03-03	The use of levobupivacaine in treating migraine
ID24065A (id)	2000-07-06	Pengobatan diabetes dengan tiozolidindinon dan sulfonilurea
NO965247D0 (no)	1996-12-09	Anvendelse av kryssbundet hemoglobin ved behandling av subarakuoidalblödning
NO981822D0 (no)	1998-04-23	Anvendelse av proteinet GAX for behandling av cancer